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Frequency of Killer Cell Immunoglobulin-like Receptors (KIRs) 
in Korean Patients with Chronic HCV Infection
Natural killer (NK) cells play an important role in innate immunity, especially in the 
response to viral infections, such as hepatitis C virus (HCV). Killer cell immunoglobulin-like 
receptors (KIRs) are the primary receptors of NK cells that mediate innate immunity. KIRs 
are also involved in acquired immunity, because some KIRs are expressed on the surface of 
certain subsets of T cells. In this study, the frequency of KIR genes, HLA-C allotypes, and 
combinations of KIR genes with their HLA-C ligands were evaluated in two different groups 
of the Korean population: controls and patients with chronic HCV infection. The study 
population consisted of 147 Korean patients with chronic HCV infection. The frequency of 
KIR2DS2 in patients with chronic HCV infection was 9.5% which was significantly lower 
than 19.5% of the control (P < 0.01). However, there were no significant differences in 
the frequency of other KIR genes, HLA-C allotypes or different combinations of KIR genes 
with their HLA-C ligands. This study can contribute to the further prospective study with a 
larger scale, suggesting the assumption that KIR2DS2 might aid in HCV clearance by 
enhancing both the innate and acquired immune responses of people in Korea.
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INTRODUCTION
Infection with hepatitis C virus (HCV) can result in both acute 
and chronic hepatitis. Acute infection rarely causes hepatic fail-
ure, but often leads to chronic infection (1). Approximately 20%-
30% of chronically infected individuals develop liver cirrhosis 
(LC) over a 20-30 yr period, and a smaller percentage progress 
to hepatocellular carcinoma (HCC) (2). A recent survey showed 
that the worldwide mortality from HCV-related LC and HCC will 
double or triple within the next two decades (1). In Korea, the 
prevalence of HCV infection in general population is estimated 
to be approximately 1%, but it is reported to be as high as 80% 
in intravenous drug users among young adults in urban areas 
(3, 4).
  In HCV infection, hepatic damage is caused primarily by the 
immune response, not by a direct cytopathic mechanism (5). 
Natural killer (NK) cells are a type of lymphocytes that plays an 
important role in the host defense against HCV infection (6, 7). 
They are critical effectors of early innate immunity toward virus 
infected cells (7). It has been reported that more than 40% of 
lymphoid cells in the liver are NK cells, compared with only 13% 
in peripheral blood cells (6, 7). NK cell function is determined 
by the net effect of signals to receptor families, including acti-
vating and inhibitory killer cell immunoglobulin-like receptors 
(KIRs) (8, 9). KIRs are a family of transmembrane glycoproteins 
expressed on the surface of NK cells and a certain subset of T 
cells, and they function as key regulators of the development, 
tolerance and activation of NK cells (9). NK cells play an impor-
tant role in a wide range of diseases, and there have been many 
studies relating KIR genotypes to disease susceptibility, includ-
ing viral infections such as HCV, autoimmune and inflammato-
ry conditions, tumor immunity, preeclampsia, and recurrent 
spontaneous abortion (10, 11).
  Combinations of KIRs form haplotypes with different inher-
ent balances between inhibition and activation of NK cells (9). 
Until recently, only 16 KIR genes and pseudogenes have been Sung PS, et al.  •  Killer Cell Immunoglobulin-like Receptors (KIRs) and Chronic HCV Infection in Korea
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identified, and group A and group B haplotypes were character-
ized by a dominance of genes encoding inhibitory and activat-
ing receptors respectively (11).
  The ligands for KIRs are human leukocyte antigen (HLA) class 
I molecules (8). Several inhibitory KIR ligands are known, includ-
ing the Bw4 motif common to a number of HLA-B and HLA-A 
alleles and a dimorphic motif that defines NK cell-mediated al-
loreactivity to known HLA-C alleles (12). Among KIRs, KIR2DL1, 
KIR2DL2, and KIR2DL3 bind their cognate HLA-C allotype C1 
or C2 with different affinities (13). Among these combinations, 
KIR2DL1/HLA-C2 is known to provide the strongest inhibition 
of NK cells, and interactions of KIR2DL2/HLA-C1 and KIR2DL3/ 
HLA-C2 follow in strength (14). Since people carry several dif-
ferent types of KIR genes and there are two HLA-C allotypes, 
various combinations of KIR and HLA-C occur, each with a dif-
ferent influence on either activating or inhibiting NK cell func-
tion (13, 14).
  Among inhibitory combinations, KIR2DL3/HLA-C1 homo-
zygosity provides the weakest inhibition of NK cells (13, 14). A 
protective association of the inhibitory receptor KIR2DL3 with 
HLA-C1 ligand and its effect on the course of HCV infection has 
been reported (15). The receptor-ligand combination of two cop-
ies of KIR2DL3 and HLA-C1 homozygosity provides weaker in-
hibitory signals than other inhibitory KIR and HLA-C receptor-
ligand combinations and thus may render a more responsive 
NK cell phenotype (15). This effect was significant in the patients 
with low HCV exposure dose, and even more pronounced in 
patients who had acquired HCV infection from intravenous drug 
use than in patients who had received a blood transfusion and 
whose innate immune system might be lethargic (15). 
  Regarding innate immunity, HCV was shown to induce early 
changes in the expression of many intrahepatic genes, includ-
ing genes involved in the type I interferon responses (12). How-
ever, these type I interferon responses in the liver do not corre-
late with the outcome of HCV infection. There were proposed 
mechanisms for the lack of correlation, including that specific 
HCV proteins might interfere with the function of NK cells (16, 
17). In this context, when inhibitory KIRs and their HLA class I 
ligands dominate, NK cell function may be impaired and HCV 
infection is more likely to become chronic (15).
  In this study, the frequency of KIR genes, HLA-C allotypes, 
and combinations of KIRs with their HLA-C ligands were evalu-
ated in two different groups: controls and patients with chronic 
HCV infection. This is the first reported study to investigate the 
incidence of KIR genes and combinations of KIRs with HLA-C 
ligands in Korean HCV carrier cohort.
MATERIALS AND METHODS
Study population
The study population consisted of 147 Korean patients with 
chronic HCV infection who had no history of blood transfusions. 
The study includes 71 males and 76 females between 20 and 78 
yr of age. Patients and controls were native Koreans and informed 
consent to participate in this study was obtained from all pati-
ents. The controls were 159 unrelated individuals who attended 
the Catholic Hemopoietic Stem Cell Information Bank. The con-
trol population was matched with the HCV-infected population 
by each risk factor of contracting HCV. The risk factors of HCV 
transmission were described as acupuncture, tattooing, hemo-
dialysis, and intravenous drug use (4). Diagnosis of chronic HCV 
infection was based on seropositivity for anti-HCV antibody us-
ing third-generation enzyme immunoassays (Abbott Laborato-
ries, North Chicago, IL, USA) and the confirmation of HCV RNA 
using the real-time polymerase chain reaction (Biosewoom Inc. 
Seoul, Korea). Additionally, HCV genotype was determined by 
VERSANT HCV genotype assay (LiPA 2.9, Innogenetics, Ghent, 
Belgium). The diagnosis of chronic liver disease due to HCV in-
fection was based on clinical or histological analyses, including 
standard serological assays, biochemical liver function tests, ra-
diological imaging, and/or liver biopsy. 
HLA-C genotyping
The genotyping for HLA-C was performed by the amplification 
refractory mutation system-polymerase chain reaction (PCR) 
method. Each reaction contained a primer mixture consisting 
of allele- or group-specific primer pairs as well as internal con-
trol primers matching nonallelic sequences. Specific amplifica-
tion of the HLA-C gene was performed using 33 primers for HLA-
C. PCR was carried out in a reaction (13 μL) containing 100 200 
ng genomic DNA, 0.8 × buffer (40 mM KCl, 1.2 mM MgCl2, 8.0 
mM Tris-HCl, pH 8.8, 0.08% Triton X-100), 5% dimethyl sulfox-
ide (DMSO), 200 μM of each dNTP, 0.25 U Taq DNA polymerase 
(Boehringer Mannheim, Germany), 1 μM of each sequence-spe-
cific primer and 0.2 μM of internal control primers. The ampli-
fications were performed in a My Cycler thermocycler (BioRad, 
Hercules, CA, USA). In total, 30 cycles were used for the ampli-
fication with the following steps: heating to 96°C for 1 min to de-
nature the DNA, denaturation at 96°C for 25 sec, annealing at 
70°C for 45 sec, and extension at 72°C for 30 sec (for the first 5 
cycles); 96°C for 25 sec, 65°C for 45 sec, 72°C for 30 sec (for the 
next 21 cycles); 96°C for 25 sec, 55°C for 60 sec, 72°C for 120 sec 
(for the last 4 cycles); and a final 1-min extension at 72°C. The 
presence or absence of PCR products was determined after sep-
aration on a 1.5% agarose gel containing 0.5 μg/mL ethidium 
bromide. HLA-C alleles were assigned to HLA-C1 or HLA-C2 
groups, as defined by KIR specificity. An individual who typed 
solely as C2 was referred to as homozygous for C2 alleles (geno-
type C2/C2), whereas an individual who typed as C1 alone was 
referred to homozygous for C1 alleles (genotype C1/C1). The 
remainders were described as C1/C2 heterozygotes.Sung PS, et al.  •  Killer Cell Immunoglobulin-like Receptors (KIRs) and Chronic HCV Infection in Korea
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Killer cell immunoglobulin-like receptor genotyping
The KIR alleles were determined by PCR using sequence-specif-
ic primers (PCR-SSP) methodology. Inhibitory KIR were typed 
for KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, 
KIR3DL2 and KIR3DL3 alleles, and activating KIRs for KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5 and KIR3DS1 alleles. 
Specific amplifications of the KIR genes were performed using 
50 forward and reverse primers. PCR was carried out with prim-
ers in a reaction (10 μL) containing 1 × buffer, 0.1-0.5 μM of each 
nucleotide primer, 2.5 mM dNTPs, 100 ng genomic DNA and 
0.5 U Taq DNA polymerase (Boehringer Mannheim). The am-
plifications were carried out in a My Cycler thermocycler (Bio-
Rad). In total, 35 cycles of PCR were completed using the follow-
ing steps: 25 sec at 91°C, 45 sec at 65°C, 30 sec at 72°C (first 4 cy-
cles); 25 sec at 91°C, 45 sec at 60°C, 30 sec at 72°C (next 26 cycles); 
25 sec at 91°C, 60 sec at 55°C, 120 sec at 72°C (last 5 cycles), and 
finally a 10 min extension at 72°C. The presence or absence of 
PCR products was determined after separation on a 2% agarose 
gel containing 0.5 μg/mL ethidium bromide.
Statistical analysis
All numerical data were described as the mean and standard 
error or as the median and range. Chi-square tests were used to 
compare the clinical parameters. In comparing the numbers of 
KIRs, independent t-test and chi-square tests were used. Statis-
tical analyses were performed using the SPSS software (SPSS 
15.0; SPSS Inc., Chicago, IL, USA). Two-tailed analysis was used, 
and results with a P value under 0.05 were considered statisti-
cally significant.
Ethics statement
This study was approved by the institutional review board of 
Seoul St. Mary’s Hospital (IRB No. KC11TISI0415). All subjects 
provided signed informed consent for research, and the use of 
the leftover specimens for this study is covered under an insti-
tutional review board protocol.
RESULTS
Demographic and clinical characteristics of the study 
population
Demographic and clinical characteristics of patients with chron-
ic HCV infection enrolled in the study are shown in Table 1. To 
identify risk factors for HCV infection in the Korean population, 
a detailed evaluation of patient histories was performed. Pati-
ents with a history of blood transfusions were excluded. Most 
chronically HCV-infected patients (72.8%) reported no history 
of risk factors of HCV infection. Reported risk factors for HCV 
transmission were acupuncture (13.6%), tattooing (5.4%), he-
modialysis (4.8%), and intravenous drug use (3.4%). Patients 
did not undergo antiviral therapy.
Frequency of KIR genes, HLA-C allotypes, and combinations 
of KIRs with their HLA-C ligands
Regarding the frequency of KIR genes, the results of our study 
showed higher frequencies of A haplotypes and lower frequen-
cies of B haplotypes in both the control group and patients with 
chronic HCV infection (Table 2). However, difference in KIR gen-
otypes was detected between the control group and chronic 
Table 1. Demographic and clinical characteristics of the study population
Characteristics    Total (n = 147)*
Mean Age (range, yr) 57.3 (20-78)
Gender (male/female)  71/76
Serum ALT level (IU/L) 78.5 ± 62.2 (20-347)
HCV genotype
   1b 
   2a 
   Undetermined 
 
    80 (54.4%)
    60 (40.8%)
    7 (4.8%)
HCV RNA titer (log copies/mL) 6.1 ± 0.8 (3.9-7.3)
Possible risk factors
   Intravenous drug user 
   Acupuncture 
   Hemodialysis
   Tatooing
   Unknown
 
    5 (3.4%)
    20 (13.6%)
    7 (4.8%)
    8 (5.4%)
  107 (72.8%)
Chronic liver diseases
   CH
   LC with HCC
147
104
  43
*This population did not undergo antiviral therapy. HCV, hepatitis C virus; ALT, alanine 
aminotransferase; CH, chronic hepatitis; LC, liver cirrhosis; HCC, hepatocellular carci-
noma.
Table 2. Frequency of killer cell immunoglobulin-like receptor (KIR) genes in controls 
and patients with chronic hepatitis C virus infection
Function      KIR gene
Normal control
n = 159 (%)
Patients
n = 147 (%)
Inhibitory 2DL
 
 
 
 
3DL
 
 
1
2
3
4
5
1
2
3
159 (100.0)
20 (12.6)
159 (100.0)
159 (100.0)
59 (37.1)
156 (98.1)
159 (100.0)
159 (100.0)
147 (100)
16 (10.9)
146 (99.3)
147 (100.0)
54 (36.7)
144 (98.0)
146 (99.3)
147 (100.0)
Activating 2DS
 
 
 
 
3DS
1
2
3
4
5
1
56 (35.2)
31 (19.5)
29 (18.2)
156 (98.1)
33 (20.8)
56 (35.2)
55 (37.4)
14* (9.5)
19 (12.9)
144 (98.0)
37 (25.2)
41 (27.9)
*P < 0.01.
Table 3. Frequency of human leukocyte antigen (HLA)-C allotypes in controls and pa-
tients with chronic hepatitis C virus infection
HLA-C allele
Normal control
n = 159 (%)
Patients
n = 147 (%)
C1C1 103 (64.8) 110 (74.8)
C1C2   48 (30.2)   31 (21.1)
C2C2   8 (5.0)   6 (4.1)Sung PS, et al.  •  Killer Cell Immunoglobulin-like Receptors (KIRs) and Chronic HCV Infection in Korea
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HCV carriers (Table 2). Among inhibitory KIRs, there were no 
significant differences between the control group and patients 
with chronic HCV infection, whereas the frequency of KIR2DS2 
of activating group in patients with chronic HCV infection was 
significantly lower than the control group (14/147 [9.5%] vs 31/ 
159 [19.5%], P < 0.01). There were no statistically significant dif-
ferences in the frequency of other activating KIR genes. 
  When evaluating the HLA-C allotype, this study found no sta-
tistically significant result (Table 3). HLA-C1/C1 had a higher 
incidence in chronic HCV carriers than in controls, but this was 
not statistically significant. 
  Also, no statistically significant difference was found in this 
study when looking at the frequency of combinations of KIRs 
with their HLA-C ligands between the control group and chron-
ic HCV carriers (Table 4).
DISCUSSION
As previously mentioned, the number of KIR genes varies among 
individuals, resulting in a heterogeneous array of possible KIR 
genes. The KIR gene diversities have already been studied in 
many different geographic populations (18-20). According to a 
previous report, the frequencies of KIR sequences observed in 
a Korean population, compared with a Caucasian population, 
showed predominance of A haplotype (KIR2DL1, 2DL3, and 
2DS4), while KIR genes on B haplotypes (KIR2DL5, 2DS1, 2DS2, 
2DS3, 2DS5, and 3DS1) with lower frequencies (20). Likewise, 
our data also showed higher frequencies of A haplotypes and 
lower frequencies of B haplotypes in both the control group and 
patients with chronic HCV infection.
  This study showed a significantly lower frequency of KIR2DS2 
among chronic HCV carriers compared with controls in a Kore-
an population (P < 0.01). This result can be a clue to the further 
investigation on HCV immunology with host genetics. KIRs are 
involved in innate immunity through their effects on NK cells 
and also in acquired immunity, because certain subsets of T 
cells express both the KIRs and T cell receptors (12). Strikingly, 
KIR2DS2 is expressed by both the innate and acquired arms of 
the immune system and is frequently included in the KIR rep-
ertoire of T cells, whereas other KIRs such as KIR2DL1 are ex-
pressed by fewer cells of acquired immunity arm (21, 22). In one 
previous study, the absence of KIR2DS2 was associated with fail-
ure of pegylated interferon and ribavirin therapy in liver trans-
plant patients with recurrent HCV infection in Americans (23). 
Likewise, for future prospective study, following assumption can 
be suggested that KIR2DS2 might aid in HCV clearance by en-
hancing both the innate and acquired immune responses of 
people, at least in a Korean population. According to a previous 
study, the frequency of KIR2DS2 genotype expression was lower 
in patients who failed early eradication of HCV and progressed 
to chronic liver disease, and it was proposed that KIR2DS2 might 
enhance the more effective cellular response, as well as the in-
nate immune response against HCV (23).
  Regarding the HLA-C allotype, this study found no statistical-
ly significant result, whereas previous studies reported different 
results that HLA-C1 homozygosity may function for HCV clear-
ance. The study by Khakoo et al. (15) suggested that HLA-C1 ho-
mozygosity might have a protective effect on HCV infected hosts, 
because of the capacity of these molecules to present antigens 
that have stronger affinities for cytotoxic T cells (15). Another 
recent study found that the frequency of HLA-C1 homozygosity 
was greater in a group of patients who achieved sustained viro-
logical response (SVR) to combined pegylated interferon and 
ribavirin therapy than in the non-response group, although the 
results were not statistically significant (24). 
  In addition, there was no statistically significant difference 
regarding the frequency of combinations of KIRs with their HLA-
C ligands. This result is also different from the data of previous 
studies (15, 25). According to the report mentioned earlier, indi-
viduals inoculated with a low HCV viral load, who had the recep-
tor-ligand combination of two copies of KIR2DL3 and HLA-C1 
homozygosity, were more likely to recover from HCV infection 
than individuals with any other genotype (15). Another recent 
study showed that patients who exhibited SVR after combined 
therapy had an increased frequency of KIR2DL3/HLA-C1 ho-
mozygosity compared with non-responders (25). In particular, 
although the protective effects of HLA-C1/KIR2DL3 were previ-
ously reported to be increased in patients with no history of blood 
transfusion (15), as our Korean study group, we did not observe 
any significant associations.
  We acknowledge that our study has several limitations. First, 
the small patient population, particularly in the genetic study, 
limits the generalization of the conclusion. Also, the patient pop-
ulation in the genetic study is likely to be biased. Next, for the 
Table 4. Frequency of combinations of killer cell immunoglobulin-like receptor (KIR) genes with their human leukocyte antigen (HLA)-C ligands in controls and patients with 
chronic hepatitis C virus infection
HLA-C allele KIR 2DS1 (%) KIR 2DS2 (%) KIR 2DS3 (%) KIR 2DL1 (%) KIR 2DL2 (%) KIR 2DL3 (%)
Control C1C1
C1C2
C2C2
34 (60.7)
19 (33.9)
3 (5.4)
23 (74.2)
  7 (22.6)
1 (3.2)
20 (69.0)
  8 (27.6)
1 (3.4)
105 (66.0)
  47 (29.6)
  7 (4.4)
12 (60.0)
  7 (35.0)
1 (5.0)
105 (66.0)
  47 (29.6)
  7 (4.4)
Patients  C1C1
C1C2
C2C2
38 (69.1)
15 (27.3)
2 (3.6)
  8 (57.1)
  6 (42.9)
0 (0.0)
14 (73.7)
  4 (21.1)
1 (5.3)
110 (74.8)
  31 (21.1)
  6 (4.1)
  8 (50.0)
  8 (50.0)
0 (0.0)
110 (75.3)
  30 (20.6)
  6 (4.1)Sung PS, et al.  •  Killer Cell Immunoglobulin-like Receptors (KIRs) and Chronic HCV Infection in Korea
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control group, patients who spontaneously cleared themselves 
of HCV would be a proper population for comparison with the 
chronically infected patients. The control group of our study con-
sisted of 159 unrelated individuals, matched with the infected 
population by each risk factor of contracting HCV. But this group 
cannot represent the cleared group of subjects. To overcome 
these limitations of our study, further prospective study with a 
larger scale is required. Also, functional studies to correlate an-
ti-HCV activity of NK cells with KIR will be necessary to further 
understand the role of KIR in HCV clearance. 
  In conclusion, this study shows a lower frequency of KIR2DS2 
among patients with chronic HCV infection than controls in a 
Korean population. This may be attributed to the impairment 
of both the innate and the acquired immune responses.
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Frequency of Killer Cell Immunoglobulin-like Receptors (KIRs) in Korean Patients 
with Chronic HCV Infection
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Killer cell immunoglobulin-like receptors (KIRs) are the receptors of natural killer (NK) cells that mediate innate immunity. A 
protective association of the inhibitory receptor KIR2DL3 with HLA-C1 ligand and its effect on the course of HCV infection was 
reported previously. Here we investigate the frequency of KIR genes, HLA-C allotypes and combinations of KIRs with HLA-C ligands 
in Korean HCV carrier cohort. The data showed that the frequency of KIR2DS2 in patients with chronic HCV infection was 
significantly lower than controls. Our study suggests that KIR2DS2 might aid in HCV clearance by enhancing immune responses.